Interaction Checker

Bexarotene interactions

Bexarotene (Targretin), a retinoid has 58 documented interactions across the FDA labels and fact sheets we index: 5 major, 27 moderate, 26 minor, and 0 where a label reports no significant interaction. Each entry below quotes the sentence behind it. This drug page is a starting point, not a verdict for your situation.

Interactions from the label

Major interactions (5)

  • AcitretinretinoidMajor

    Acitretin is contraindicated in cases of hypersensitivity (e.g., angioedema, urticaria) to the preparation (acitretin or excipients) or to other retinoids . (Acitretin label, Contraindications)

  • GemfibrozilfibrateMajor

    Because of a potential drug-drug interaction, avoid gemfibrozil use with TARGRETIN [ see Drug Interactions (7) ]. (Bexarotene label, Warnings and precautions)

  • Minocyclinetetracycline antibioticMajor

    Avoid concomitant use of isotretinoin and EMROSI because isotretinoin, a systemic retinoid, is also known to cause idiopathic intracranial hypertension. (Minocycline label, Warnings and precautions)

  • Tetracyclinetetracycline antibioticMajor

    Concomitant use of isotretinoin and tetracycline should be avoided because isotretinoin, a systemic retinoid, is also known to cause pseudotumor cerebri. (Tetracycline label, Warnings)

  • TretinoinretinoidMajor

    Tretinoin capsules are contraindicated in patients with a known hypersensitivity to tretinoin capsules, any of its components, or other retinoids. (Tretinoin label, Contraindications)

Moderate interactions (27)

  • AlcoholAlcoholModerate

    Patients with CTCL who have risk factors for pancreatitis (e.g., prior pancreatitis, uncontrolled hyperlipidemia, excessive alcohol consumption, uncontrolled diabetes mellitus, biliary tract disease, and medications known to increase triglyceride levels or to be associated with pancreatic toxicity) may be at greater risk for pancreatitis associated with TARGRETIN… (Bexarotene label, Warnings and precautions)

  • Calcium chlorideModerate

    Drugs That Increase the Risk of Hypercalcemia Increase frequency of monitoring of calcium concentrations in patients taking concomitant Calcium Chloride Injection and other drugs that increase the risk of hypercalcemia (e.g., calcipotriene, estrogen, lithium, parathyroid hormone, teriparatide, thiazide diuretics, Vitamin A, and Vitamin D). (Calcium chloride label, Drug interactions)

  • Elexacaftor, tezacaftor, and ivacaftorModerate

    Patients with elevated vitamin A levels may be at increased risk. (Elexacaftor, tezacaftor, and ivacaftor label, Warnings and precautions)

  • GlimepiridesulfonylureaModerate

    Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (Bexarotene label, Warnings and precautions)

  • GlipizidesulfonylureaModerate

    Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (Bexarotene label, Warnings and precautions)

  • Glipizide and metforminsulfonylureaModerate

    Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (Bexarotene label, Warnings and precautions)

  • GlyburidesulfonylureaModerate

    Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (Bexarotene label, Warnings and precautions)

  • Glyburide and metforminsulfonylureaModerate

    Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (Bexarotene label, Warnings and precautions)

  • Insulin aspartinsulinModerate

    Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (Bexarotene label, Warnings and precautions)

  • Insulin degludecinsulinModerate

    Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (Bexarotene label, Warnings and precautions)

  • Insulin detemirinsulinModerate

    Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (Bexarotene label, Warnings and precautions)

  • Insulin glargineinsulinModerate

    Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (Bexarotene label, Warnings and precautions)

  • Insulin lisproinsulinModerate

    Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (Bexarotene label, Warnings and precautions)

  • Insulin regular (human)insulinModerate

    Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (Bexarotene label, Warnings and precautions)

  • IvacaftorCYP3A4 inhibitorModerate

    Patients with elevated vitamin A levels may be at increased risk. (Ivacaftor label, Warnings and precautions)

  • Levothyroxinethyroid hormoneModerate

    Monitor and replace thyroid hormone if needed. (Bexarotene label, Warnings and precautions)

  • Levothyroxine and liothyroninethyroid hormoneModerate

    Monitor and replace thyroid hormone if needed. (Bexarotene label, Warnings and precautions)

  • Liothyroninethyroid hormoneModerate

    Monitor and replace thyroid hormone if needed. (Bexarotene label, Warnings and precautions)

  • Methimazoleantithyroid drugModerate

    Monitor and replace thyroid hormone if needed. (Bexarotene label, Warnings and precautions)

  • MethotrexateimmunosuppressantModerate

    Monitor patients receiving XATMEP with other potential hepatotoxins (e.g., azathioprine, retinoids, and sulfasalazine) for possible signs of hepatotoxicity. (Methotrexate label, Drug interactions)

  • OrlistatModerate

    The effect of ORLISTAT on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known at this time [see Clinical Pharmacology (12.3) , and Warnings and Precautions (5.1) ] . (Orlistat label, Drug interactions)

  • PioglitazonethiazolidinedioneModerate

    Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (Bexarotene label, Warnings and precautions)

  • Pioglitazone and glimepiridethiazolidinedioneModerate

    Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (Bexarotene label, Warnings and precautions)

  • Pioglitazone and metforminthiazolidinedioneModerate

    Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (Bexarotene label, Warnings and precautions)

  • Propylthiouracilantithyroid drugModerate

    Monitor and replace thyroid hormone if needed. (Bexarotene label, Warnings and precautions)

  • Teriparatidethyroid hormoneModerate

    Monitor and replace thyroid hormone if needed. (Bexarotene label, Warnings and precautions)

  • TirzepatideGLP-1 receptor agonistModerate

    Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (Bexarotene label, Warnings and precautions)

Minor mentions (26)

  • Amlodipine and atorvastatindihydropyridine calcium channel blockerMinor

    Atorvastatin was used in 48% (73/152) of patients with CTCL. (Bexarotene label, Warnings and precautions)

  • AtorvastatinstatinMinor

    Atorvastatin was used in 48% (73/152) of patients with CTCL. (Bexarotene label, Warnings and precautions)

  • Calcium gluconateMinor

    Drugs that may cause hypercalcemia: Vitamin D, vitamin A, thiazide diuretics, estrogen, calcipotriene and teriparatide administration may cause hypercalcemia. (Calcium gluconate label, Drug interactions)

  • Conjugated estrogensestrogenMinor

    Drug products which may be affected include oral or other systemic hormonal contraceptives. (Bexarotene label, Drug interactions)

  • Conjugated estrogens and bazedoxifeneestrogenMinor

    Drug products which may be affected include oral or other systemic hormonal contraceptives. (Bexarotene label, Drug interactions)

  • Desogestrel and ethinyl estradioloral contraceptiveMinor

    Drug products which may be affected include oral or other systemic hormonal contraceptives. (Bexarotene label, Drug interactions)

  • Drospirenone and ethinyl estradioloral contraceptiveMinor

    Drug products which may be affected include oral or other systemic hormonal contraceptives. (Bexarotene label, Drug interactions)

  • Esterified estrogens and methyltestosteroneestrogenMinor

    Drug products which may be affected include oral or other systemic hormonal contraceptives. (Bexarotene label, Drug interactions)

  • EstradiolestrogenMinor

    Drug products which may be affected include oral or other systemic hormonal contraceptives. (Bexarotene label, Drug interactions)

  • Estradiol and dienogestoral contraceptiveMinor

    Drug products which may be affected include oral or other systemic hormonal contraceptives. (Bexarotene label, Drug interactions)

  • Estradiol and norethindroneestrogenMinor

    Drug products which may be affected include oral or other systemic hormonal contraceptives. (Bexarotene label, Drug interactions)

  • Ethynodiol diacetate and ethinyl estradioloral contraceptiveMinor

    Drug products which may be affected include oral or other systemic hormonal contraceptives. (Bexarotene label, Drug interactions)

  • Etonogestrel and ethinyl estradiolestrogenMinor

    Drug products which may be affected include oral or other systemic hormonal contraceptives. (Bexarotene label, Drug interactions)

  • Fluconazoleazole antifungalMinor

    Vitamin A Based on a case report in one patient receiving combination therapy with all-trans-retinoid acid (an acid form of vitamin A) and fluconazole, central nervous system (CNS) related undesirable effects have developed in the form of pseudotumor cerebri, which disappeared after discontinuation of fluconazole treatment. (Fluconazole label, Drug interactions)

  • FulvestrantestrogenMinor

    Drug products which may be affected include oral or other systemic hormonal contraceptives. (Bexarotene label, Drug interactions)

  • LevonorgestrelprogestinMinor

    Drug products which may be affected include oral or other systemic hormonal contraceptives. (Bexarotene label, Drug interactions)

  • Levonorgestrel and ethinyl estradioloral contraceptiveMinor

    Drug products which may be affected include oral or other systemic hormonal contraceptives. (Bexarotene label, Drug interactions)

  • MedroxyprogesteroneprogestinMinor

    Drug products which may be affected include oral or other systemic hormonal contraceptives. (Bexarotene label, Drug interactions)

  • MegestrolprogestinMinor

    Drug products which may be affected include oral or other systemic hormonal contraceptives. (Bexarotene label, Drug interactions)

  • MifepristoneCYP3A4 inhibitorMinor

    Drug products which may be affected include oral or other systemic hormonal contraceptives. (Bexarotene label, Drug interactions)

  • Norelgestromin and ethinyl estradiolestrogenMinor

    Drug products which may be affected include oral or other systemic hormonal contraceptives. (Bexarotene label, Drug interactions)

  • NorethindroneprogestinMinor

    Drug products which may be affected include oral or other systemic hormonal contraceptives. (Bexarotene label, Drug interactions)

  • Norethindrone and ethinyl estradioloral contraceptiveMinor

    Drug products which may be affected include oral or other systemic hormonal contraceptives. (Bexarotene label, Drug interactions)

  • Norgestimate and ethinyl estradioloral contraceptiveMinor

    Drug products which may be affected include oral or other systemic hormonal contraceptives. (Bexarotene label, Drug interactions)

  • Norgestrel and ethinyl estradioloral contraceptiveMinor

    Drug products which may be affected include oral or other systemic hormonal contraceptives. (Bexarotene label, Drug interactions)

  • ProgesteroneprogestinMinor

    Drug products which may be affected include oral or other systemic hormonal contraceptives. (Bexarotene label, Drug interactions)

Check Bexarotene against everything you take. Add your full list; every pair is checked at once.

Open in the checker

Not medical advice. Severity reflects the label's wording, not your circumstances. A "major" flag can be routine under supervision and a "minor" one can matter at high doses. Ask a pharmacist.